Mr. Lam Kong
Chairman; Chief Executive; President; executive Director
Board of Directors and Chief ExecutiveThe business, the people and the ownership behind CMS.
Business overview
China Medical System operates healthcare-related businesses, including an integrated pharmaceutical business and a skin health business. Its research portfolio also includes drug development programmes described in its annual report.
Listed security
Board & management
Chairman; Chief Executive; President; executive Director
Board of Directors and Chief ExecutiveChief Financial Officer; Vice-president; executive Director
Board of Directorsindependent non-executive Director
Board of Directorsindependent non-executive Director
Board of Directorsindependent non-executive Director
Board of DirectorsRoles listed in CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025; current appointments are not independently verified.
Holdings
Interest in controlled corporation; 1,167,564,000 (L) shares; approximately 47.86% of the Company; held through Treasure Sea Limited, a company wholly owned by him (controlling shareholder)
Directors' and Chief Executive's interests in shares of the Company; long position (L); deemed/corporate interest, not nomineeTotal interests include direct and deemed holdings and may overlap across holders. These percentages should not be added together.
Group structure
| Company | Market | Ownership interest |
|---|---|---|
| Kangzhe Hunan31 December 2025; 2024 also 100% indirectlyPDF p. 178 | PRC; 100% indirectly held; Production of medicines | |
| Tibet Kangzhe Enterprise Management Co. Ltd.31 December 2025; 2024 also 100% indirectlyPDF p. 178 | PRC; 100% indirectly held; Investment holding | |
| Shenzhen Kangzhe31 December 2025; 2024 also 100% indirectlyPDF p. 178 | PRC; 100% indirectly held; Marketing, promotion and sale of drugs | |
| Sino Talent31 December 2025; 2024 also 100% indirectlyPDF p. 178 | Hong Kong; 100% indirectly held; Investment holding | |
| Sky United31 December 2025; 2024 also 100% indirectlyPDF p. 178 | Hong Kong; 100% indirectly held; Trading of drugs | |
| Kangzhe Pharmaceutical Investment Co., Ltd.31 December 2025; 2024 also 100% indirectlyPDF p. 178 | PRC; 100% indirectly held; Investment holding | |
| Tianjin Kangzhe31 December 2025; 2024 also 100% indirectlyPDF p. 178 | PRC; 100% indirectly held; Marketing, promotion and sale of drugs | |
| Tibet Kangzhe Development31 December 2025; 2024 also 100% indirectlyPDF p. 178 | PRC; 100% indirectly held; Marketing, promotion and sale of drugs | |
| CMS Bridging Limited31 December 2025; 2024 also 100% indirectlyPDF p. 178 | Hong Kong; 100% indirectly held; Investment holding | |
| CMS Medical Venture Investment (HK) Limited31 December 2025; 2024 also 100% indirectlyPDF p. 178 | Hong Kong; 100% indirectly held; Investment holding | |
| CMS International Development and Management Limited31 December 2025; 2024 also 100% indirectlyPDF p. 178 | Macau; 100% indirectly held; Trading of drugs | |
| CMS Pharma DMCC31 December 2025; 2024 also 100% indirectlyPDF p. 178 | Dubai; 100% indirectly held; Trading of drugs | |
| Shanghai Dermavon Pharmaceutical Co., Ltd31 December 2025; 2024 also 100% indirectlyPDF p. 178 | PRC; 100% indirectly held; Marketing and promotion of drugs | |
| Hainan Dermavon Pharmaceutical Technology Co., Ltd31 December 2025; 2024 also 100% indirectlyPDF p. 178 | PRC; 100% indirectly held; Marketing, promotion and sale of drugs | |
| Hainan Kangzhe Venture Capital Co. Ltd31 December 2025; 2024 also 100% indirectlyPDF p. 178 | PRC; 100% indirectly held; Investment holding | |
| Dermavon Limited31 December 2025; 2024 also 100% indirectlyPDF p. 178 | Hong Kong; 100% indirectly held; Trading of drugs | |
| RXILIENT MEDICAL (HONG KONG) LIMITED31 December 2025; 2024 also 100% indirectlyPDF p. 178 | Hong Kong; 100% indirectly held; Trading of drugs | |
| Heling Medical (Guangzhou) Company Limited31 December 2025; 2024 also 60% indirectlyPDF p. 179 | PRC; 60% indirectly held; Production of skincare products | |
| Hainan Kangzhe Vision Technology Co., Ltd31 December 2025; 2024 also 100% indirectlyPDF p. 179 | PRC; 100% indirectly held; Marketing, promotion and sale of drugs | |
| CMS Vision International Management Limited31 December 2025; 2024 also 100% indirectlyPDF p. 179 | Macau; 100% indirectly held; Trading of drugs | |
| DERMAVON INTERNATIONAL BUSINESS LIMITED31 December 2025; 2024 also 100% indirectlyPDF p. 179 | Macau; 100% indirectly held; Trading of drugs | |
Ownership interests and geographic information follow the annual report. Comparative years and footnote markers retain the report’s notation.
Senior executives
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Mr. Ma Lieyi | General Manager of the Operations and Management Center of the Group | Senior management | PDF p. 47 |
| Mr. Jiang Qingfu | General Manager of Cardio-cerebrovascular/Digestion Business (Shenzhen Kangzhe) of the Group | Senior management | PDF p. 47 |
| Ms. Li Yufang | General Manager of the Finance Center of the Group | Senior management | PDF p. 47 |
| Mr. Fan Jie | Deputy General Manager; General Manager of Off-hospital Business and Supply Chain Center of the Group | Senior management | PDF p. 47 |
| Mr. Cai Ping | Deputy General Manager; General Manager of the Strategic Market of the Group | Senior management | PDF p. 47 |
| Mr. Huang Anjun | General Manager of Dermatology Business (Dermavon) of the Group | Senior management | PDF p. 48 |
| Dr. Peng Huaizheng | Chief Business Officer of the Group | Senior management | PDF p. 48 |
| Mr. Jiang Fei | Chief Investment Officer (Greater China) of the Group | Senior management | PDF p. 48 |
| Mr. James Stearns | Chief Investment Officer (Europe and America) of the Group | Senior management | PDF p. 48 |
| Ms. Wang Linlang | General Manager of Ophthalmology Business (CMS Vision) of the Group | Senior management | PDF p. 48 |
| Ms. Wu Sanyan | Company Secretary; Director of the Legal Department of the Group | Company Secretary | PDF p. 48 |
Extracted from CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025 and checked against the cited pages; see the original report for full context.
Related parties, people & properties
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Tibet Pharmaceutical | 1,468,071 RMB'000 | Group; Associate; Promotion income; 2025 (2024: 1,395,476) | PDF p. 171 |
| ETC | 16,183 RMB'000 | Group; Associate; Purchase of goods; 2025 (2024: 9,337) | PDF p. 171 |
| ETC | 5,505 RMB'000 | Group; Associate; Promotion income; 2025 (2024: 9,110) | PDF p. 171 |
| A&B (HK) Company Limited | 2,018 RMB'000 | Group; Related party; Royalty expenses; 2025 (2024: 2,699) | PDF p. 171 |
| PharmaGend Global Medical Services Pte. Ltd. | 9,408 RMB'000 | Group; Related party; Service fee; 2025 (2024: -) | PDF p. 171 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Contingent Liabilities | the Group had no material contingent liabilities | Group · As at 2025-12-31 | PDF p. 44 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Total emoluments | 13,895 RMB'000 | All directors and chief executive total, year ended 31 December 2025 (2024: 17,244) | PDF p. 120 |
| Total emoluments | 17,244 RMB'000 | All directors and chief executive total, year ended 31 December 2024 | PDF p. 120 |
| Total | 11 number of persons | Senior management incl. Company Secretary, excluding directors, 2025; bands HK$1,500,001-HK$3,500,000 | PDF p. 59 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Employees | 6,415 employees | Group · As at 2025-12-31 | PDF p. 59 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Exclusive distribution agreement for Lidoderm Lidocaine Cataplasms | on 12 February 2026, the Group through subsidiaries of the Company entered into an exclusive distribution agreement with Teikoku Pharma USA, Inc. | Group · As at 2026-02-12 | PDF p. 36 |
| Approval of Drug Clinical Trials for CMS-D017 | On 3 February 2026, the NMPA has approved the Group to conduct clinical trials in healthy participants in China | Group · As at 2026-02-03 | PDF p. 36 |
| Final dividend declared | the Board of Directors have declared a final dividend of RMB0.1366 per ordinary share | Group; year ended 31 December 2025 | PDF p. 125 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Outlook | The Group will continue to anchor on unmet clinical needs, deepen innovation upgrading, strengthen commercialization capabilities, advance industrial internationalization and accelerate digital intelligence-enabled operational upgrades. | Chairman's Statement | PDF p. 10 |
Extracted from CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025 and checked against the cited pages; see the original report for full context.
Source: CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025 ↗
Corporate information